DEVELOPMENT OF MOLECULAR CHAPERONE INHIBITORS FOR (RE) SENSITIZATION OF CRPC TO ENZALUTAMIDE AND ABIRATERONE AND TO SYNERGIZE WITH METABOLIC INHIBITORS
$831,643FY2019Defense Health AgencyDOD
The Geneva Foundation
Investigators
View source on USAspending →DEVELOPMENT OF MOLECULAR CHAPERONE INHIBITORS FOR (RE) SENSITIZATION OF CRPC TO ENZALUTAMIDE AND ABIRATERONE AND TO SYNERGIZE WITH METABOLIC INHIBITORS · GrantIndex